Synergy Empire Ltd 8-K/A

What Happened

• Synergy Empire Ltd reported that it executed an Acquisition and Stock Purchase Agreement (July 29, 2024) and consummated the purchase of Meluha Therapeutics Berhad on March 28, 2025.
• As consideration the company issued 10,000,000 shares of its Series A preferred stock at a stated value of $0.2155 per share (aggregate $2,155,000). Each Series A preferred share carries the same voting rights as one common share.
• Following the closing, two former Meluha shareholders—Ramesh A/L Saravanamuthu and Abdul Jalil bin Jidon—received 3,359,438 and 3,188,437 Series A shares, respectively, giving them ~29.1% and ~27.7% of the Company’s voting power and effective control over board elections and shareholder matters.

Key Details

• Agreement date: July 29, 2024; closing date: March 28, 2025.
• Consideration: 10,000,000 Series A preferred shares valued at $0.2155/share (total $2,155,000).
• Voting/control: Ramesh — 3,359,438 shares (~29.1%); Abdul — 3,188,437 shares (~27.7%); together they control a majority of voting power.
• Business shift: Synergy Empire shifted from food & beverage consultancy to regenerative medicine/biopharma via Meluha (products cited: myCell and Chondrogen); company applied for GMP certification by July 2026 and plans clinical testing thereafter.
• Regulatory/exemption note: Preferred shares were issued pursuant to exemptions under Section 4(a)(2) and Regulation S (holders reported as non-U.S. persons).
• Financial reporting: Item 9.01 disclosures (audited financials of Meluha and pro forma combined info) will be filed by amendment within 71 days.
• Internal controls: Management disclosed material weaknesses (insufficient segregation of duties; lack of U.S. GAAP accounting personnel) and described planned remediation steps.

Why It Matters

• Control: The Series A issuance concentrated voting power in two individuals who can unilaterally control board elections and major shareholder decisions—an important governance factor for investors.
• Business pivot: The acquisition moves Synergy Empire from F&B to biotech/regenerative medicine, changing the company’s market, regulatory profile and operational risks (e.g., GMP certification, clinical testing, IP/regulatory compliance).
• Financial transparency: Audited financials and pro forma results for the acquired business were not yet furnished in the filing and will be provided later; investors should review those when filed to assess the deal’s financial impact.
• Operational/ reporting risk: Identified internal-control weaknesses and the need to add qualified U.S. GAAP accounting staff could affect timeliness and reliability of SEC reporting until remediated.